Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2060149,plasma half-life,"When compared to that of non-immune acromegalic patients, the plasma half-life of octreotide in these two patients was 300 and 450 vs 110 min in those with no detectable octreotide antibodies.",Effects of antibodies against octreotide in two patients with acromegaly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060149/),min,300,80,DB00104,Octreotide
,2060149,plasma half-life,"When compared to that of non-immune acromegalic patients, the plasma half-life of octreotide in these two patients was 300 and 450 vs 110 min in those with no detectable octreotide antibodies.",Effects of antibodies against octreotide in two patients with acromegaly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060149/),min,450,81,DB00104,Octreotide
,2060149,plasma half-life,"When compared to that of non-immune acromegalic patients, the plasma half-life of octreotide in these two patients was 300 and 450 vs 110 min in those with no detectable octreotide antibodies.",Effects of antibodies against octreotide in two patients with acromegaly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060149/),min,110,82,DB00104,Octreotide
,2060149,interval of maximum,The sole observed consequence of the immunization was a marked prolongation of the interval of maximum GH inhibition from a mean of 5 to 8 and 10 h in the two patients described after octreotide injection.,Effects of antibodies against octreotide in two patients with acromegaly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060149/),h,5,83,DB00104,Octreotide
,2060149,interval of maximum,The sole observed consequence of the immunization was a marked prolongation of the interval of maximum GH inhibition from a mean of 5 to 8 and 10 h in the two patients described after octreotide injection.,Effects of antibodies against octreotide in two patients with acromegaly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060149/),h,10,84,DB00104,Octreotide
,8287633,plasma half-life,"Compared with the somatostatin, octreotide is highly resistant to enzymatic degradation and has a prolonged plasma half-life of about 100 minutes in humans, allowing its use in the long term treatment of various pathological conditions.",Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287633/),min,100,6862,DB00104,Octreotide
,8287633,volume of distribution,The volume of distribution of octreotide ranges from 18 to 30L.,Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287633/),l,18 to 30,6863,DB00104,Octreotide
,8287633,serum distribution half-life,Calculated serum distribution half-life ranges from 72 to 98 minutes.,Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287633/),min,72 to 98,6864,DB00104,Octreotide
,8287633,bioavailability,"After subcutaneous injection, absorption appears rapid and complete and bioavailability is about 100%.",Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287633/),%,100,6865,DB00104,Octreotide
,8287633,peak plasma concentrations,Mean peak plasma concentrations are between 2 and 4 micrograms/L in patients receiving 50 to 100 micrograms.,Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287633/),[μg] / [l],2 and 4,6866,DB00104,Octreotide
,8287633,elimination half-life,The elimination half-life is about 90 to 110 minutes.,Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287633/),min,90 to 110,6867,DB00104,Octreotide
,8287633,Total clearance,Total clearance in healthy individuals is about 160 ml/min (9.6 L/h).,Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287633/),[ml] / [min],160,6868,DB00104,Octreotide
,17225119,half-life,"Gallium-68 is a metallic positron emitter with a half-life of 68 min that is ideal for the in vivo use of small molecules, such as [68Ga-DOTA,Tyr3]octreotide, in the diagnostic imaging of somatostatin receptor-positive tumours.",Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17225119/),min,68,11178,DB00104,Octreotide
,11136293,first-order elimination (Ke,"A one-compartment linear model was constructed which consisted of two absorption processes, characterized by KIR and KSR, rate constants for immediate-release and sustained-release, respectively, with first-order elimination (Ke; 1.05 h-1).",Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136293/),1/[h],1.05,14673,DB00104,Octreotide
,11136293,first-order absorption (KIR,"The surface, unencapsulated drug was immediately absorbed into the central compartment with first-order absorption (KIR; 0.0312 h-1), while the microencapsulated drug was first released in a zero-order fashion into a depot before being absorbed into the central compartment with first-order absorption (KSR; 0.00469 h-1) during a period of tau (1680 h).",Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136293/),1/[h],0.0312,14674,DB00104,Octreotide
,11136293,first-order absorption (KSR,"The surface, unencapsulated drug was immediately absorbed into the central compartment with first-order absorption (KIR; 0.0312 h-1), while the microencapsulated drug was first released in a zero-order fashion into a depot before being absorbed into the central compartment with first-order absorption (KSR; 0.00469 h-1) during a period of tau (1680 h).",Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136293/),1/[h],0.00469,14675,DB00104,Octreotide
>,23872204,m/z,"Octreotide and internal standard (triptorelin) were identified in positive electrospray ionization mode using ion transitions of m/z 512>120 and 890>249, respectively.",Validation of a rapid liquid chromatography-tandem mass spectrometric assay for the determination of octreotide plasma concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23872204/),,512,28295,DB00104,Octreotide
>,23872204,m/z,"Octreotide and internal standard (triptorelin) were identified in positive electrospray ionization mode using ion transitions of m/z 512>120 and 890>249, respectively.",Validation of a rapid liquid chromatography-tandem mass spectrometric assay for the determination of octreotide plasma concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23872204/),,120,28296,DB00104,Octreotide
>,23872204,m/z,"Octreotide and internal standard (triptorelin) were identified in positive electrospray ionization mode using ion transitions of m/z 512>120 and 890>249, respectively.",Validation of a rapid liquid chromatography-tandem mass spectrometric assay for the determination of octreotide plasma concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23872204/),,89,28297,DB00104,Octreotide
>,23872204,m/z,"Octreotide and internal standard (triptorelin) were identified in positive electrospray ionization mode using ion transitions of m/z 512>120 and 890>249, respectively.",Validation of a rapid liquid chromatography-tandem mass spectrometric assay for the determination of octreotide plasma concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23872204/),,249,28298,DB00104,Octreotide
,23872204,recovery,"The recovery and ion suppression effect ranged between 79.7 and 84.5% and between -8.1 and -21.3%, respectively.",Validation of a rapid liquid chromatography-tandem mass spectrometric assay for the determination of octreotide plasma concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23872204/),%,79.7 and 84.5,28299,DB00104,Octreotide
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],18,30139,DB00104,Octreotide
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],36,30140,DB00104,Octreotide
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],70,30141,DB00104,Octreotide
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],17,30142,DB00104,Octreotide
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],30,30143,DB00104,Octreotide
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],84,30144,DB00104,Octreotide
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],66,30145,DB00104,Octreotide
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],71,30146,DB00104,Octreotide
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],60,30147,DB00104,Octreotide
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],69,30148,DB00104,Octreotide
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],78,30149,DB00104,Octreotide
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],73,30150,DB00104,Octreotide
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,7.6,30151,DB00104,Octreotide
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,8.2,30152,DB00104,Octreotide
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,8.8,30153,DB00104,Octreotide
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9.8,30154,DB00104,Octreotide
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,10,30155,DB00104,Octreotide
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9.5,30156,DB00104,Octreotide
,10443692,t 1/2,"Regression analysis disclosed no relationship between serum estradiol concentrations and peak serum GH levels, GH t 1/2, or Vo. GH t 1/2 values were also invariant of menstrual cycle stage, e.g. t 1/2 values of 8.1+/-0.5, 9.1+/-1.0, and 8.1+/-0.4 min for the early follicular, late follicular, and midluteal phases, respectively.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,8.1,30157,DB00104,Octreotide
,10443692,t 1/2,"Regression analysis disclosed no relationship between serum estradiol concentrations and peak serum GH levels, GH t 1/2, or Vo. GH t 1/2 values were also invariant of menstrual cycle stage, e.g. t 1/2 values of 8.1+/-0.5, 9.1+/-1.0, and 8.1+/-0.4 min for the early follicular, late follicular, and midluteal phases, respectively.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9.1,30158,DB00104,Octreotide
,10443692,t 1/2,"Regression analysis disclosed no relationship between serum estradiol concentrations and peak serum GH levels, GH t 1/2, or Vo. GH t 1/2 values were also invariant of menstrual cycle stage, e.g. t 1/2 values of 8.1+/-0.5, 9.1+/-1.0, and 8.1+/-0.4 min for the early follicular, late follicular, and midluteal phases, respectively.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,8.1,30159,DB00104,Octreotide
,10443692,normalized MCRs,"Corresponding normalized MCRs were 319+/-39 (early follicular), 340+/-48 (late follicular), and 340+/-71 (midluteal) L/m2 x day in women and 336+/-50 L/m2 x day in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[l] / [d·m2],319,30160,DB00104,Octreotide
,10443692,normalized MCRs,"Corresponding normalized MCRs were 319+/-39 (early follicular), 340+/-48 (late follicular), and 340+/-71 (midluteal) L/m2 x day in women and 336+/-50 L/m2 x day in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[l] / [d·m2],340,30161,DB00104,Octreotide
,10443692,normalized MCRs,"Corresponding normalized MCRs were 319+/-39 (early follicular), 340+/-48 (late follicular), and 340+/-71 (midluteal) L/m2 x day in women and 336+/-50 L/m2 x day in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[l] / [d·m2],340,30162,DB00104,Octreotide
,10443692,normalized MCRs,"Corresponding normalized MCRs were 319+/-39 (early follicular), 340+/-48 (late follicular), and 340+/-71 (midluteal) L/m2 x day in women and 336+/-50 L/m2 x day in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[l] / [d·m2],336,30163,DB00104,Octreotide
,10443692,t 1/2,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9,30164,DB00104,Octreotide
,10443692,t 1/2,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,12,30165,DB00104,Octreotide
,10443692,t 1/2,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,15,30166,DB00104,Octreotide
,10443692,steady state serum GH concentrations,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],0.5,30167,DB00104,Octreotide
,10443692,steady state serum GH concentrations,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],2.1,30168,DB00104,Octreotide
,10443692,steady state serum GH concentrations,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],7.5,30169,DB00104,Octreotide
,10443692,t 1/2,"In a third analysis in the same volunteers, stopping the constant iv infusions revealed t 1/2 values of GH decay from equilibrium of 26+/-5 and 23+/-2.3 min for the two higher GH infusion rates.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,26,30170,DB00104,Octreotide
,10443692,t 1/2,"In a third analysis in the same volunteers, stopping the constant iv infusions revealed t 1/2 values of GH decay from equilibrium of 26+/-5 and 23+/-2.3 min for the two higher GH infusion rates.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,23,30171,DB00104,Octreotide
,10443692,t 1/2,"In a fourth paradigm, endogenous GH t 1/2 values, as assessed in the same individuals by deconvolution analysis of overnight (10-min sampled) serum GH concentration profiles, averaged 18+/-1.3 min.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,18,30172,DB00104,Octreotide
,10443692,t 1/2,"In summary, the foregoing clinical experiments in healthy men and women indicate that 1) the nonequilibrium GH t 1/2, (body surface area-normalized) Vo, and MCR are independent of GH dose, sex, menstrual cycle stage, and serum estradiol concentrations; 2) the GH t 1/2 calculated after iv bolus injection is significantly (50%) shorter than that assessed during or after steady-state GH infusions or endogenously (overnight) by deconvolution analysis; and 3) the descending rank order of GH t 1/2 values in healthy volunteers is approximately: decay from steady state (23+/-2.3 min) > endogenously secreted GH (18+/-1.3 min) > during equilibrium infusion (15+/-1 min) > after bolus infusion (9.8+/-0.8 min).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,23,30173,DB00104,Octreotide
,10443692,t 1/2,"In summary, the foregoing clinical experiments in healthy men and women indicate that 1) the nonequilibrium GH t 1/2, (body surface area-normalized) Vo, and MCR are independent of GH dose, sex, menstrual cycle stage, and serum estradiol concentrations; 2) the GH t 1/2 calculated after iv bolus injection is significantly (50%) shorter than that assessed during or after steady-state GH infusions or endogenously (overnight) by deconvolution analysis; and 3) the descending rank order of GH t 1/2 values in healthy volunteers is approximately: decay from steady state (23+/-2.3 min) > endogenously secreted GH (18+/-1.3 min) > during equilibrium infusion (15+/-1 min) > after bolus infusion (9.8+/-0.8 min).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,18,30174,DB00104,Octreotide
,10443692,t 1/2,"In summary, the foregoing clinical experiments in healthy men and women indicate that 1) the nonequilibrium GH t 1/2, (body surface area-normalized) Vo, and MCR are independent of GH dose, sex, menstrual cycle stage, and serum estradiol concentrations; 2) the GH t 1/2 calculated after iv bolus injection is significantly (50%) shorter than that assessed during or after steady-state GH infusions or endogenously (overnight) by deconvolution analysis; and 3) the descending rank order of GH t 1/2 values in healthy volunteers is approximately: decay from steady state (23+/-2.3 min) > endogenously secreted GH (18+/-1.3 min) > during equilibrium infusion (15+/-1 min) > after bolus infusion (9.8+/-0.8 min).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,15,30175,DB00104,Octreotide
,10443692,t 1/2,"In summary, the foregoing clinical experiments in healthy men and women indicate that 1) the nonequilibrium GH t 1/2, (body surface area-normalized) Vo, and MCR are independent of GH dose, sex, menstrual cycle stage, and serum estradiol concentrations; 2) the GH t 1/2 calculated after iv bolus injection is significantly (50%) shorter than that assessed during or after steady-state GH infusions or endogenously (overnight) by deconvolution analysis; and 3) the descending rank order of GH t 1/2 values in healthy volunteers is approximately: decay from steady state (23+/-2.3 min) > endogenously secreted GH (18+/-1.3 min) > during equilibrium infusion (15+/-1 min) > after bolus infusion (9.8+/-0.8 min).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9.8,30176,DB00104,Octreotide
,9643619,hepatic blood flow,Somatostatin and octreotide elicit an indistinguishable hepatic blood flow decrease from 1.49 to 1.07 l min(-1).,Assessment of hepatic blood flow using continuous infusion of high clearance drugs. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643619/),[l] / [min],1.49,46025,DB00104,Octreotide
,9643619,hepatic blood flow,Somatostatin and octreotide elicit an indistinguishable hepatic blood flow decrease from 1.49 to 1.07 l min(-1).,Assessment of hepatic blood flow using continuous infusion of high clearance drugs. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643619/),[l] / [min],1.07,46026,DB00104,Octreotide
,9643619,half-life,Return to baseline takes much longer for octreotide (half-life 126+/-104 min) than for somatostatin (half-life 4.29+/-3.55 min).,Assessment of hepatic blood flow using continuous infusion of high clearance drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643619/),min,126,46027,DB00104,Octreotide
,9643619,half-life,Return to baseline takes much longer for octreotide (half-life 126+/-104 min) than for somatostatin (half-life 4.29+/-3.55 min).,Assessment of hepatic blood flow using continuous infusion of high clearance drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643619/),min,4.29,46028,DB00104,Octreotide
,22539587,peak plasma concentration,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),[ng] / [ml],3.77,52140,DB00104,Octreotide
,22539587,peak plasma concentration,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),[ng] / [ml],3.97,52141,DB00104,Octreotide
,22539587,area under the curve,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),[h·ng] / [ml],16.2,52142,DB00104,Octreotide
,22539587,area under the curve,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),[h·ng] / [ml],12.1,52143,DB00104,Octreotide
≥,22539587,time,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),[ng] / [ml],0.5,52144,DB00104,Octreotide
,22539587,time,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),h,7.67,52145,DB00104,Octreotide
,22539587,time,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),h,5.88,52146,DB00104,Octreotide
,2898717,peak levels,"The plasma concentrations of SMS were dose-responsive and the peak levels were 1.61 +/- 0.09, 4.91 +/- 0.30 and 8.52 +/- 1.18 ng/ml, which were observed at 30, 15 and 45 min after the injection of 25, 50 and 100 micrograms of SMS, respectively.",Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898717/),[ng] / [ml],1.61,52972,DB00104,Octreotide
,2898717,peak levels,"The plasma concentrations of SMS were dose-responsive and the peak levels were 1.61 +/- 0.09, 4.91 +/- 0.30 and 8.52 +/- 1.18 ng/ml, which were observed at 30, 15 and 45 min after the injection of 25, 50 and 100 micrograms of SMS, respectively.",Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898717/),[ng] / [ml],4.91,52973,DB00104,Octreotide
,2898717,peak levels,"The plasma concentrations of SMS were dose-responsive and the peak levels were 1.61 +/- 0.09, 4.91 +/- 0.30 and 8.52 +/- 1.18 ng/ml, which were observed at 30, 15 and 45 min after the injection of 25, 50 and 100 micrograms of SMS, respectively.",Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898717/),[ng] / [ml],8.52,52974,DB00104,Octreotide
,2898717,plasma disappearance half-time,Mean plasma disappearance half-time of SMS was estimated to be 110 +/- 3 min.,Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898717/),min,110,52975,DB00104,Octreotide
,9830576,circulating half life,Following subcutaneous administration of 50 micrograms octreotide the circulating half life (range 2.4 to 4.79 h) was prolonged whereas the clearance (range 2.101 to 4.775 L/h) was decreased compared to healthy controls.,Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9830576/),h,2.4 to 4.79,60292,DB00104,Octreotide
,9830576,clearance,Following subcutaneous administration of 50 micrograms octreotide the circulating half life (range 2.4 to 4.79 h) was prolonged whereas the clearance (range 2.101 to 4.775 L/h) was decreased compared to healthy controls.,Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9830576/),[l] / [h],2.101 to 4.775,60293,DB00104,Octreotide
,25771364,β(max),The simultaneous emission of imageable gamma photons [208 keV (11%) and 113 keV (6.4%)] along with particulate β(-) emission [β(max) = 497 keV] makes it a theranostically desirable radioisotope.,Theranostic Applications of Lutetium-177 in Radionuclide Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25771364/),kev,497,64014,DB00104,Octreotide
,11216519,half-life,"64Cu (half-life, 12.7 h; beta+, 0.653 MeV [17.4%]; beta-, 0.579 MeV [39%]) has shown potential as a radioisotope for PET imaging and radiotherapy.",64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11216519/),h,12.7,68465,DB00104,Octreotide
,11216519,beta+,"64Cu (half-life, 12.7 h; beta+, 0.653 MeV [17.4%]; beta-, 0.579 MeV [39%]) has shown potential as a radioisotope for PET imaging and radiotherapy.",64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11216519/),Mev,0.653,68466,DB00104,Octreotide
,11216519,beta-,"64Cu (half-life, 12.7 h; beta+, 0.653 MeV [17.4%]; beta-, 0.579 MeV [39%]) has shown potential as a radioisotope for PET imaging and radiotherapy.",64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11216519/),Mev,0.579,68467,DB00104,Octreotide
,26425883,relative bioavailability,The relative bioavailability was about 3%.,Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26425883/),%,3,71623,DB00104,Octreotide
,15493847,flow rate,"HPLC-MS was carried out using a Waters Xetrra C18 column and a mobile phase consisting of CH3 OH-1% HAc (80 : 20), the flow rate was 0.2 mL x min(-1), and the internal standard was 6, 7, 4'-OH-isoflavone, the SIR ions for quantification were m/z 1 014.4 for octreotide and m/z 317.6 for internal standard.",[Determination of octreotide in human plasma by HPLC-MS with solid-phase extraction and study on the relative bioavailability of domestic and imported octreotide injections]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15493847/),[ml] / [min],0.2,77279,DB00104,Octreotide
,15493847,m/z,"HPLC-MS was carried out using a Waters Xetrra C18 column and a mobile phase consisting of CH3 OH-1% HAc (80 : 20), the flow rate was 0.2 mL x min(-1), and the internal standard was 6, 7, 4'-OH-isoflavone, the SIR ions for quantification were m/z 1 014.4 for octreotide and m/z 317.6 for internal standard.",[Determination of octreotide in human plasma by HPLC-MS with solid-phase extraction and study on the relative bioavailability of domestic and imported octreotide injections]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15493847/),,1 014.4,77280,DB00104,Octreotide
,15493847,m/z,"HPLC-MS was carried out using a Waters Xetrra C18 column and a mobile phase consisting of CH3 OH-1% HAc (80 : 20), the flow rate was 0.2 mL x min(-1), and the internal standard was 6, 7, 4'-OH-isoflavone, the SIR ions for quantification were m/z 1 014.4 for octreotide and m/z 317.6 for internal standard.",[Determination of octreotide in human plasma by HPLC-MS with solid-phase extraction and study on the relative bioavailability of domestic and imported octreotide injections]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15493847/),,317.6,77281,DB00104,Octreotide
,15493847,C(max),"The mean C(max) were (19 +/- 10) microg x L(-1) and (19 +/- 11) microg x L(-1), T(max) were (0.50 +/- 0.15) h and (0.52 +/- 0.20) h, T1/2 were (1.5 +/- 0.8) h and (1.5 +/- 0.8) h, AUC(0-7 h) were (50 +/- 25) h x microg x L(-1) and (50 +/- 25) h x microg x L(-1), respectively.",[Determination of octreotide in human plasma by HPLC-MS with solid-phase extraction and study on the relative bioavailability of domestic and imported octreotide injections]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15493847/),[μg] / [l],19,77282,DB00104,Octreotide
,15493847,C(max),"The mean C(max) were (19 +/- 10) microg x L(-1) and (19 +/- 11) microg x L(-1), T(max) were (0.50 +/- 0.15) h and (0.52 +/- 0.20) h, T1/2 were (1.5 +/- 0.8) h and (1.5 +/- 0.8) h, AUC(0-7 h) were (50 +/- 25) h x microg x L(-1) and (50 +/- 25) h x microg x L(-1), respectively.",[Determination of octreotide in human plasma by HPLC-MS with solid-phase extraction and study on the relative bioavailability of domestic and imported octreotide injections]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15493847/),[μg] / [l],19,77283,DB00104,Octreotide
,15493847,T(max),"The mean C(max) were (19 +/- 10) microg x L(-1) and (19 +/- 11) microg x L(-1), T(max) were (0.50 +/- 0.15) h and (0.52 +/- 0.20) h, T1/2 were (1.5 +/- 0.8) h and (1.5 +/- 0.8) h, AUC(0-7 h) were (50 +/- 25) h x microg x L(-1) and (50 +/- 25) h x microg x L(-1), respectively.",[Determination of octreotide in human plasma by HPLC-MS with solid-phase extraction and study on the relative bioavailability of domestic and imported octreotide injections]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15493847/),h,0.50,77284,DB00104,Octreotide
,15493847,T(max),"The mean C(max) were (19 +/- 10) microg x L(-1) and (19 +/- 11) microg x L(-1), T(max) were (0.50 +/- 0.15) h and (0.52 +/- 0.20) h, T1/2 were (1.5 +/- 0.8) h and (1.5 +/- 0.8) h, AUC(0-7 h) were (50 +/- 25) h x microg x L(-1) and (50 +/- 25) h x microg x L(-1), respectively.",[Determination of octreotide in human plasma by HPLC-MS with solid-phase extraction and study on the relative bioavailability of domestic and imported octreotide injections]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15493847/),h,0.52,77285,DB00104,Octreotide
,15493847,T1/2,"The mean C(max) were (19 +/- 10) microg x L(-1) and (19 +/- 11) microg x L(-1), T(max) were (0.50 +/- 0.15) h and (0.52 +/- 0.20) h, T1/2 were (1.5 +/- 0.8) h and (1.5 +/- 0.8) h, AUC(0-7 h) were (50 +/- 25) h x microg x L(-1) and (50 +/- 25) h x microg x L(-1), respectively.",[Determination of octreotide in human plasma by HPLC-MS with solid-phase extraction and study on the relative bioavailability of domestic and imported octreotide injections]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15493847/),h,1.5,77286,DB00104,Octreotide
,15493847,AUC(0-7 h),"The mean C(max) were (19 +/- 10) microg x L(-1) and (19 +/- 11) microg x L(-1), T(max) were (0.50 +/- 0.15) h and (0.52 +/- 0.20) h, T1/2 were (1.5 +/- 0.8) h and (1.5 +/- 0.8) h, AUC(0-7 h) were (50 +/- 25) h x microg x L(-1) and (50 +/- 25) h x microg x L(-1), respectively.",[Determination of octreotide in human plasma by HPLC-MS with solid-phase extraction and study on the relative bioavailability of domestic and imported octreotide injections]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15493847/),[h·μg] / [l],50,77287,DB00104,Octreotide
,15493847,relative bioavailability,The relative bioavailability of domestic to imported injection was 101% +/- 10%.,[Determination of octreotide in human plasma by HPLC-MS with solid-phase extraction and study on the relative bioavailability of domestic and imported octreotide injections]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15493847/),%,101,77288,DB00104,Octreotide
,27253622,half-life,"The α-octreotide conjugate had a half-life of ∼2 weeks, and showed an excellent correlation of in vitro and in vivo drug release.",Subcutaneously Administered Self-Cleaving Hydrogel-Octreotide Conjugates Provide Very Long-Acting Octreotide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27253622/),weeks,∼2,78138,DB00104,Octreotide
,15951474,apparent t1/2,Lanreotide 90-mg profile showed C(max) on day 1 then elimination (apparent t1/2 25.5 days); 120-mg profile was underproportional.,Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951474/),d,25.5,78221,DB00104,Octreotide
,15951474,C(mean),"Steady-state PK of octreotide 20 mg/28 d suggested a C(mean) of 1216 rhog/mL (range, 1065-1585) with low fluctuation index (43%).",Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951474/),[rhog] / [ml],1216,78222,DB00104,Octreotide
,15951474,C(mean),"Steady-state PK of lanreotide 90 mg/28 d suggested a C(mean) of 4455 rhog/mL (range, 2499-9279) with high fluctuation index (152%).",Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951474/),[rhog] / [ml],4455,78223,DB00104,Octreotide
,25087170,t½,"The niobium-90 radioisotope ((90)Nb) holds considerable promise for use in immuno-PET, due to its decay parameters (t½ = 14.6h, positron yield=53%, Eß(+)(mean) = 0.35 MeV and Eß(+)(max) = 1.5 MeV).","Desferrioxamine as an appropriate chelator for 90Nb: comparison of its complexation properties for M-Df-Octreotide (M = Nb, Fe, Ga, Zr). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25087170/),h,14.6,79561,DB00104,Octreotide
,25087170,Eß(+),"The niobium-90 radioisotope ((90)Nb) holds considerable promise for use in immuno-PET, due to its decay parameters (t½ = 14.6h, positron yield=53%, Eß(+)(mean) = 0.35 MeV and Eß(+)(max) = 1.5 MeV).","Desferrioxamine as an appropriate chelator for 90Nb: comparison of its complexation properties for M-Df-Octreotide (M = Nb, Fe, Ga, Zr). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25087170/),Mev,0.35,79562,DB00104,Octreotide
,25087170,Eß(+)(max),"The niobium-90 radioisotope ((90)Nb) holds considerable promise for use in immuno-PET, due to its decay parameters (t½ = 14.6h, positron yield=53%, Eß(+)(mean) = 0.35 MeV and Eß(+)(max) = 1.5 MeV).","Desferrioxamine as an appropriate chelator for 90Nb: comparison of its complexation properties for M-Df-Octreotide (M = Nb, Fe, Ga, Zr). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25087170/),Mev,1.5,79563,DB00104,Octreotide
,25087170,half-life,"For the purpose of studying the complexation properties the niobium radioisotope (95)Nb was used as an analogue of (90)Nb, by virtue of its longer half-life (35 days) and lower cost (reactor-based production).","Desferrioxamine as an appropriate chelator for 90Nb: comparison of its complexation properties for M-Df-Octreotide (M = Nb, Fe, Ga, Zr). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25087170/),d,35,79564,DB00104,Octreotide
,11807604,tumour-to-blood ratio,"At 1 h the tumour-to-blood ratio of ( 3) was 28.2+/-7.3, and the tumour-to-muscle ratio, 147+/-48.","Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11807604/),,28.2,88419,DB00104,Octreotide
,11807604,tumour-to-muscle ratio,"At 1 h the tumour-to-blood ratio of ( 3) was 28.2+/-7.3, and the tumour-to-muscle ratio, 147+/-48.","Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11807604/),,147,88420,DB00104,Octreotide
,16003295,apparent clearance,The apparent clearance for SOM230 is approximately half of that for octreotide (8.0 L/h versus 15.8 L/h).,"Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003295/),[l] / [h],8.0,99429,DB00104,Octreotide
,16003295,apparent clearance,The apparent clearance for SOM230 is approximately half of that for octreotide (8.0 L/h versus 15.8 L/h).,"Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003295/),[l] / [h],15.8,99430,DB00104,Octreotide
,16003295,elimination half-life,The elimination half-life for SOM230 is about 5 times longer than that for octreotide (11.8 hours versus 2.3 hours).,"Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003295/),h,11.8,99431,DB00104,Octreotide
,16003295,elimination half-life,The elimination half-life for SOM230 is about 5 times longer than that for octreotide (11.8 hours versus 2.3 hours).,"Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003295/),h,2.3,99432,DB00104,Octreotide
,16003295,half of the maximum drug effect is observed (EC50),"The test drug concentration level at which half of the maximum drug effect is observed (EC50) is 46 and 553 pg/mL for octreotide and SOM230, respectively, with large interpatient variability (coefficients of variation, 164% and 65%, respectively), mainly attributable to the heterogeneous responses among patients.","Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003295/),[pg] / [ml],46,99433,DB00104,Octreotide
,16003295,half of the maximum drug effect is observed (EC50),"The test drug concentration level at which half of the maximum drug effect is observed (EC50) is 46 and 553 pg/mL for octreotide and SOM230, respectively, with large interpatient variability (coefficients of variation, 164% and 65%, respectively), mainly attributable to the heterogeneous responses among patients.","Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003295/),[pg] / [ml],553,99434,DB00104,Octreotide
,1619006,areas,Average areas (+/- SEM) under the serum octreotide curves were: 2000 micrograms: 4597 +/- 536; 1000 micrograms: 1923 +/- 439; 500 micrograms: 957 +/- 168; and 100 micrograms sc: 896 +/- 81 micrograms.L-1.min (n = 13).,A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619006/),[min·μg] / [l],4597,100879,DB00104,Octreotide
,1619006,areas,Average areas (+/- SEM) under the serum octreotide curves were: 2000 micrograms: 4597 +/- 536; 1000 micrograms: 1923 +/- 439; 500 micrograms: 957 +/- 168; and 100 micrograms sc: 896 +/- 81 micrograms.L-1.min (n = 13).,A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619006/),[min·μg] / [l],1923,100880,DB00104,Octreotide
,1619006,areas,Average areas (+/- SEM) under the serum octreotide curves were: 2000 micrograms: 4597 +/- 536; 1000 micrograms: 1923 +/- 439; 500 micrograms: 957 +/- 168; and 100 micrograms sc: 896 +/- 81 micrograms.L-1.min (n = 13).,A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619006/),[min·μg] / [l],957,100881,DB00104,Octreotide
,1619006,areas,Average areas (+/- SEM) under the serum octreotide curves were: 2000 micrograms: 4597 +/- 536; 1000 micrograms: 1923 +/- 439; 500 micrograms: 957 +/- 168; and 100 micrograms sc: 896 +/- 81 micrograms.L-1.min (n = 13).,A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619006/),[min·μg] / [l],896,100882,DB00104,Octreotide
,1619006,relative availability,"The calculated relative availability was 27% +/- 0.03; 22% +/- 0.05; 22% +/- 0.03, respectively, for the three nasal doses.",A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619006/),%,27,100883,DB00104,Octreotide
,1619006,relative availability,"The calculated relative availability was 27% +/- 0.03; 22% +/- 0.05; 22% +/- 0.03, respectively, for the three nasal doses.",A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619006/),%,22,100884,DB00104,Octreotide
,1619006,relative availability,"The calculated relative availability was 27% +/- 0.03; 22% +/- 0.05; 22% +/- 0.03, respectively, for the three nasal doses.",A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619006/),%,22,100885,DB00104,Octreotide
,1619006,t1/2 ka,"The rate of absorption after intranasally administered octreotide was greater than after sc application: t1/2 ka: 7.1 +/- 1.6; 7.9 +/- 1.6; 11.3 +/- 1.9, respectively, vs. 24.1 +/- 2.5 min, whereas the rates of disappearance were similar.",A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619006/),min,7.1,100886,DB00104,Octreotide
,1619006,t1/2 ka,"The rate of absorption after intranasally administered octreotide was greater than after sc application: t1/2 ka: 7.1 +/- 1.6; 7.9 +/- 1.6; 11.3 +/- 1.9, respectively, vs. 24.1 +/- 2.5 min, whereas the rates of disappearance were similar.",A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619006/),min,7.9,100887,DB00104,Octreotide
,1619006,t1/2 ka,"The rate of absorption after intranasally administered octreotide was greater than after sc application: t1/2 ka: 7.1 +/- 1.6; 7.9 +/- 1.6; 11.3 +/- 1.9, respectively, vs. 24.1 +/- 2.5 min, whereas the rates of disappearance were similar.",A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619006/),min,11.3,100888,DB00104,Octreotide
,1619006,t1/2 ka,"The rate of absorption after intranasally administered octreotide was greater than after sc application: t1/2 ka: 7.1 +/- 1.6; 7.9 +/- 1.6; 11.3 +/- 1.9, respectively, vs. 24.1 +/- 2.5 min, whereas the rates of disappearance were similar.",A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619006/),min,24.1,100889,DB00104,Octreotide
,2644151,half-life,A mean half-life of 115 min was calculated.,Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2644151/),min,115,103155,DB00104,Octreotide
,2575511,Vdss,"The plasma pharmacokinetics of Sandostatin were as follows: Vdss = 0.4 liter/kg, C/t = 4.2 ml/min, and t1/2 2.0 hr; this half-life was by far longer than that of somatostatin.","Disposition of sandostatin, a new synthetic somatostatin analogue, in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575511/),[l] / [kg],0.4,107671,DB00104,Octreotide
,2575511,C/t,"The plasma pharmacokinetics of Sandostatin were as follows: Vdss = 0.4 liter/kg, C/t = 4.2 ml/min, and t1/2 2.0 hr; this half-life was by far longer than that of somatostatin.","Disposition of sandostatin, a new synthetic somatostatin analogue, in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575511/),[ml] / [min],4.2,107672,DB00104,Octreotide
,2575511,t1/2,"The plasma pharmacokinetics of Sandostatin were as follows: Vdss = 0.4 liter/kg, C/t = 4.2 ml/min, and t1/2 2.0 hr; this half-life was by far longer than that of somatostatin.","Disposition of sandostatin, a new synthetic somatostatin analogue, in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575511/),h,2.0,107673,DB00104,Octreotide
,2575511,protein binding,The in vitro protein binding amounted to 59% in rat plasma; no Sandostatin was taken up by blood cells.,"Disposition of sandostatin, a new synthetic somatostatin analogue, in rats. ",Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575511/),%,59,107674,DB00104,Octreotide
,10806600,Cmin,"After the injection, mean serum octreotide concentration initially increased rapidly, reached the maximum (Cmax, day 1 = 0.96 +/- 0.25 ng/ml) approximately 1.5 hours after dosing, and declined thereafter until 24 hours postdose (Cmin, 24 h = 0.088 +/- 0.093 ng/ml).","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),[ng] / [ml],0.088,108464,DB00104,Octreotide
,10806600,plateau height (Cplateau (2-112d,"The plateau height (Cplateau (2-112d, 60%)) was 1.68 +/- 0.88 ng/ml, and the duration (delta plateau, 60%) was 30.2 +/- 15.7 days.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),[ng] / [ml],60,108465,DB00104,Octreotide
,10806600,plateau height (Cplateau (2-112d,"The plateau height (Cplateau (2-112d, 60%)) was 1.68 +/- 0.88 ng/ml, and the duration (delta plateau, 60%) was 30.2 +/- 15.7 days.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),[ng] / [ml],1.68,108466,DB00104,Octreotide
,10806600,duration (delta plateau,"The plateau height (Cplateau (2-112d, 60%)) was 1.68 +/- 0.88 ng/ml, and the duration (delta plateau, 60%) was 30.2 +/- 15.7 days.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),%,60,108467,DB00104,Octreotide
,10806600,duration (delta plateau,"The plateau height (Cplateau (2-112d, 60%)) was 1.68 +/- 0.88 ng/ml, and the duration (delta plateau, 60%) was 30.2 +/- 15.7 days.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),d,30.2,108468,DB00104,Octreotide
,10806600,"integrated concentration-time curve, AUC0-112d","The integrated concentration-time curve, AUC0-112d, was 2819 +/- 782 (ng.h/ml), and the apparent half-life (t1/2) was 169 hours.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),[h·ng] / [ml],2819,108469,DB00104,Octreotide
,10806600,apparent half-life (t1/2),"The integrated concentration-time curve, AUC0-112d, was 2819 +/- 782 (ng.h/ml), and the apparent half-life (t1/2) was 169 hours.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),h,169,108470,DB00104,Octreotide
,10806600,"concentration, Cavg","To assess the variability, the drug concentrations were determined hourly for 8 hours on day 28, and the mean octreotide concentration, Cavg, day 28' was 1.55 +/- 1.26 ng/ml.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),[ng] / [ml],1.55,108471,DB00104,Octreotide
,14668579,peak delivered amount,"Efficiency of delivery ranged from 0.1% to 2.7% of the total infused dose of 0.18 microg, corresponding to a mean peak delivered amount of 1.8 +/- 1.9 ng.",Site-specific intracoronary delivery of octreotide in humans: a pharmacokinetic study to determine dose-efficacy in restenosis prevention. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14668579/),ng,1.8,121255,DB00104,Octreotide
,14668579,Total locally bioavailable,Total locally bioavailable 111In-octreotide reached 2.28 +/- 2.15 ng h.,Site-specific intracoronary delivery of octreotide in humans: a pharmacokinetic study to determine dose-efficacy in restenosis prevention. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14668579/),h·ng,2.28,121256,DB00104,Octreotide
,19042837,time to administration,There was no difference in the median time to administration of the second medication (3 hours).,"A pilot phase II randomized, cross-over, double-blinded, controlled efficacy study of octreotide versus hyoscine hydrobromide for control of noisy breathing at the end-of-life. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042837/),h,3,123177,DB00104,Octreotide
,28010844,absorption peak time (Tmax),"More importantly, octreotide was found to eliminate from the intestines rapidly, the absorption peak time (Tmax) appeared at 40 min and the half-life time (t1/2) was calculated as 37.7 min according to the elimination curves.",Pharmacokinetic study based on a matrix-assisted laser desorption/ionization quadrupole ion trap time-of-flight imaging mass microscope combined with a novel relative exposure approach: A case of octreotide in mouse target tissues. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28010844/),min,40,129707,DB00104,Octreotide
,28010844,half-life time (t1/2),"More importantly, octreotide was found to eliminate from the intestines rapidly, the absorption peak time (Tmax) appeared at 40 min and the half-life time (t1/2) was calculated as 37.7 min according to the elimination curves.",Pharmacokinetic study based on a matrix-assisted laser desorption/ionization quadrupole ion trap time-of-flight imaging mass microscope combined with a novel relative exposure approach: A case of octreotide in mouse target tissues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28010844/),min,37.7,129708,DB00104,Octreotide
,8222296,area under the curve,"In fact, the area under the curve (mU/l/150 min) was 912.8 +/- 170.6 for controls and 3524.8 +/- 642.8 for chronic renal failure patients (P < 0.005).",Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222296/),[mu] / [150·l·min],912.8,132350,DB00104,Octreotide
,8222296,area under the curve,"In fact, the area under the curve (mU/l/150 min) was 912.8 +/- 170.6 for controls and 3524.8 +/- 642.8 for chronic renal failure patients (P < 0.005).",Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222296/),[mu] / [150·l·min],3524.8,132351,DB00104,Octreotide
,8222296,half-life,"The GH half-life was 13.8 +/- 1.6 and 26.4 +/- 2.9 minutes for control and uraemic subjects respectively (P < 0.05), and the metabolic clearance rate MCR (ml/min/m2) was 265.3 +/- 50.6 for controls and 79.9 +/- 16.4 for uraemic patients (P < 0.05).",Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222296/),min,13.8,132352,DB00104,Octreotide
,8222296,half-life,"The GH half-life was 13.8 +/- 1.6 and 26.4 +/- 2.9 minutes for control and uraemic subjects respectively (P < 0.05), and the metabolic clearance rate MCR (ml/min/m2) was 265.3 +/- 50.6 for controls and 79.9 +/- 16.4 for uraemic patients (P < 0.05).",Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222296/),min,26.4,132353,DB00104,Octreotide
,8222296,metabolic clearance rate MCR,"The GH half-life was 13.8 +/- 1.6 and 26.4 +/- 2.9 minutes for control and uraemic subjects respectively (P < 0.05), and the metabolic clearance rate MCR (ml/min/m2) was 265.3 +/- 50.6 for controls and 79.9 +/- 16.4 for uraemic patients (P < 0.05).",Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222296/),[ml] / [m2·min],265.3,132354,DB00104,Octreotide
,8222296,metabolic clearance rate MCR,"The GH half-life was 13.8 +/- 1.6 and 26.4 +/- 2.9 minutes for control and uraemic subjects respectively (P < 0.05), and the metabolic clearance rate MCR (ml/min/m2) was 265.3 +/- 50.6 for controls and 79.9 +/- 16.4 for uraemic patients (P < 0.05).",Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222296/),[ml] / [m2·min],79.9,132355,DB00104,Octreotide
,8222296,mean residence time,The GH mean residence time (minutes) (MRT) calculated was 12.0 +/- 0.5 for controls and 31.8 +/- 4.6 for chronic renal failure patients (P < 0.05).,Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222296/),min,12.0,132356,DB00104,Octreotide
,8222296,mean residence time,The GH mean residence time (minutes) (MRT) calculated was 12.0 +/- 0.5 for controls and 31.8 +/- 4.6 for chronic renal failure patients (P < 0.05).,Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222296/),min,31.8,132357,DB00104,Octreotide
,8222296,half-life of the second phase,"Contrary to previous estimates, GH elimination kinetics follows a bi-exponential model and in normal subjects the GH half-life of the second phase is 13.8 +/- 1.6 minutes.",Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222296/),min,13.8,132358,DB00104,Octreotide
,25160589,I max,The drug effect was modeled by using an inhibitory E max model (I max = 0.96 and IC50 = 13.9 nM) to reduce the ability of glucagon to increase the glucose production rate (GPROD).,"A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160589/),,0.96,133560,DB00104,Octreotide
,25160589,IC50,The drug effect was modeled by using an inhibitory E max model (I max = 0.96 and IC50 = 13.9 nM) to reduce the ability of glucagon to increase the glucose production rate (GPROD).,"A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160589/),nM,13.9,133561,DB00104,Octreotide
,25160589,E max,"In addition, an E max model (E max = 0.79 and EC50 = 575 nM) to increase glucagon secretion by the drug was used to account for the increased glucagon concentrations prechallenge (via compensatory feedback).","A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160589/),,0.79,133562,DB00104,Octreotide
,25160589,EC50,"In addition, an E max model (E max = 0.79 and EC50 = 575 nM) to increase glucagon secretion by the drug was used to account for the increased glucagon concentrations prechallenge (via compensatory feedback).","A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160589/),nM,575,133563,DB00104,Octreotide
,2871684,half-life,"Clearance studies (n = 6) for this peptide showed a prolonged half-life in plasma, 113 min, following single sc injections of 50 or 100 micrograms.",Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871684/),min,113,135186,DB00104,Octreotide
,23864305,initial clearance half-time,LuTate demonstrated biexponential blood clearance with an initial clearance half-time of 21 min.,Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23864305/),min,21,137149,DB00104,Octreotide
,29653971,total-body effective doses,The total-body effective doses were 0.205 ± 0.161 mSv/MBq for 177Lu-DOTA-EB-TATE and 0.174 ± 0.072 mSv/MBq for 177Lu-DOTATATE.,"Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29653971/),[msv] / [Mbq],0.205,142552,DB00104,Octreotide
,29653971,total-body effective doses,The total-body effective doses were 0.205 ± 0.161 mSv/MBq for 177Lu-DOTA-EB-TATE and 0.174 ± 0.072 mSv/MBq for 177Lu-DOTATATE.,"Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29653971/),[msv] / [Mbq],0.174,142553,DB00104,Octreotide
,29355620,zeta potential,"SEDDS containing the octreotide-deoxycholate, -decanoate and -docusate ion pair exhibited a mean droplet size of 152nm, 112nm and 191nm and a zeta potential of -3.7, -4.6 and -5.7mV, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),mv,-,149414,DB00104,Octreotide
,29355620,zeta potential,"SEDDS containing the octreotide-deoxycholate, -decanoate and -docusate ion pair exhibited a mean droplet size of 152nm, 112nm and 191nm and a zeta potential of -3.7, -4.6 and -5.7mV, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),mv,3.7,149415,DB00104,Octreotide
,29355620,zeta potential,"SEDDS containing the octreotide-deoxycholate, -decanoate and -docusate ion pair exhibited a mean droplet size of 152nm, 112nm and 191nm and a zeta potential of -3.7, -4.6 and -5.7mV, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),mv,4.6,149416,DB00104,Octreotide
,29355620,zeta potential,"SEDDS containing the octreotide-deoxycholate, -decanoate and -docusate ion pair exhibited a mean droplet size of 152nm, 112nm and 191nm and a zeta potential of -3.7, -4.6 and -5.7mV, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),mv,5.7,149417,DB00104,Octreotide
,29355620,log DSEDDS/release medium,"They were completely stable towards degradation by lipase and showed a log DSEDDS/release medium of 1.7, 1.8 and 2.7, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),,1.7,149418,DB00104,Octreotide
,29355620,log DSEDDS/release medium,"They were completely stable towards degradation by lipase and showed a log DSEDDS/release medium of 1.7, 1.8 and 2.7, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),,1.8,149419,DB00104,Octreotide
,29355620,log DSEDDS/release medium,"They were completely stable towards degradation by lipase and showed a log DSEDDS/release medium of 1.7, 1.8 and 2.7, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),,2.7,149420,DB00104,Octreotide
,29355620,diffusion coefficient,"The diffusion coefficient of these SEDDS was in the range of 0.03, 0.11 and 0.17×10-9cm2/s, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),[cm2] / [s],0.03,149421,DB00104,Octreotide
,29355620,diffusion coefficient,"The diffusion coefficient of these SEDDS was in the range of 0.03, 0.11 and 0.17×10-9cm2/s, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),[cm2] / [s],0.11,149422,DB00104,Octreotide
,29355620,diffusion coefficient,"The diffusion coefficient of these SEDDS was in the range of 0.03, 0.11 and 0.17×10-9cm2/s, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),[cm2] / [s],0.17×10-9,149423,DB00104,Octreotide
,16437218,SUV,"The SUV for (68)Ga-DOTATOC was highly variable, with a range from 0.877 to 28.07 (mean 8.73).",Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16437218/),,8.73,153860,DB00104,Octreotide
,16437218,FD,"The FD values varied from 1.10 to 1.45, with a mean of 1.33.",Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16437218/),,1.33,153861,DB00104,Octreotide
,26076191,bioavailability,"The relative octreotide bioavailability of depot variants vs. octreotide IR ranged from 0.68 (90% confidence interval [CI] 0.61, 0.76) to 0.91 (90% CI 0.81, 1.02) and, vs. octreotide LAR, was approximately four- to five-fold greater: 3.97 (90% CI 3.35, 4.71) to 5.27 ng ml(-1) h (90% CI 4.43, 6.27).",Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26076191/),[h·ng] / [ml],3.,153960,DB00104,Octreotide
,26076191,bioavailability,"The relative octreotide bioavailability of depot variants vs. octreotide IR ranged from 0.68 (90% confidence interval [CI] 0.61, 0.76) to 0.91 (90% CI 0.81, 1.02) and, vs. octreotide LAR, was approximately four- to five-fold greater: 3.97 (90% CI 3.35, 4.71) to 5.27 ng ml(-1) h (90% CI 4.43, 6.27).",Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26076191/),[h·ng] / [ml],5.27,153961,DB00104,Octreotide
,9186832,clearance,"The average clearance (+/-SEM) was 151 +/- 15 ml/min in normals compared to 102 +/- 9 (p < 0.05) and 105 +/- 9 (p < 0.05) in patients with compensated and decompensated cirrhosis, respectively.",The pharmacokinetics of octreotide in cirrhosis and in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186832/),[ml] / [min],151,155212,DB00104,Octreotide
,9186832,clearance,"The average clearance (+/-SEM) was 151 +/- 15 ml/min in normals compared to 102 +/- 9 (p < 0.05) and 105 +/- 9 (p < 0.05) in patients with compensated and decompensated cirrhosis, respectively.",The pharmacokinetics of octreotide in cirrhosis and in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186832/),,102,155213,DB00104,Octreotide
,9186832,clearance,"The average clearance (+/-SEM) was 151 +/- 15 ml/min in normals compared to 102 +/- 9 (p < 0.05) and 105 +/- 9 (p < 0.05) in patients with compensated and decompensated cirrhosis, respectively.",The pharmacokinetics of octreotide in cirrhosis and in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186832/),,105,155214,DB00104,Octreotide
,9186832,maximum serum concentration,This difference was also reflected by an increased maximum serum concentration during the infusion period of 9797 +/- 580 ng/l in the patients with cirrhosis compared to 7081 +/- 547 ng/l (p = 0.006) in normals.,The pharmacokinetics of octreotide in cirrhosis and in healthy man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186832/),[ng] / [l],9797,155215,DB00104,Octreotide
,9186832,maximum serum concentration,This difference was also reflected by an increased maximum serum concentration during the infusion period of 9797 +/- 580 ng/l in the patients with cirrhosis compared to 7081 +/- 547 ng/l (p = 0.006) in normals.,The pharmacokinetics of octreotide in cirrhosis and in healthy man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186832/),[ng] / [l],7081,155216,DB00104,Octreotide
,9186832,serum half-life for the beta-phase (T1/2 beta),"The serum half-life for the beta-phase (T1/2 beta) was 165 +/- 26 min in normals, 200 +/- 21 min in the compensated and 216 +/- 26 min in the decompensated group (NS).",The pharmacokinetics of octreotide in cirrhosis and in healthy man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186832/),min,165,155217,DB00104,Octreotide
,9186832,serum half-life for the beta-phase (T1/2 beta),"The serum half-life for the beta-phase (T1/2 beta) was 165 +/- 26 min in normals, 200 +/- 21 min in the compensated and 216 +/- 26 min in the decompensated group (NS).",The pharmacokinetics of octreotide in cirrhosis and in healthy man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186832/),min,200,155218,DB00104,Octreotide
,9186832,serum half-life for the beta-phase (T1/2 beta),"The serum half-life for the beta-phase (T1/2 beta) was 165 +/- 26 min in normals, 200 +/- 21 min in the compensated and 216 +/- 26 min in the decompensated group (NS).",The pharmacokinetics of octreotide in cirrhosis and in healthy man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186832/),min,216,155219,DB00104,Octreotide
,8392486,residence half-life,First PET studies with [68Ga]-DFO-SMS showed a rapid accumulation in the tumor and a residence half-life at the tumor site of about 6 hours.,New octreotide derivatives for in vivo targeting of somatostatin receptor-positive tumors for single photon emission computed tomography (SPECT) and positron emission tomography (PET). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392486/),h,6,165002,DB00104,Octreotide
,1589410,relative bioavailability,"Compared to a 50-micrograms subcutaneous injection, the nasal spray formulation without STDHF had a mean relative bioavailability of 17.9%.",Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1589410/),%,17.9,168557,DB00104,Octreotide
,1589410,bioavailability,"For nasal formulations containing 3 and 1.65% (w/v) of STDHF, the bioavailability increased to 29.0 and 25.7%, respectively.",Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1589410/),%,29.0,168558,DB00104,Octreotide
,1589410,bioavailability,"For nasal formulations containing 3 and 1.65% (w/v) of STDHF, the bioavailability increased to 29.0 and 25.7%, respectively.",Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1589410/),%,25.7,168559,DB00104,Octreotide
,1589410,bioavailability,"The enhancement of nasal absorption was dependent on the STDHF concentrations as shown by decreasing the amounts to 1.2 and 0.8% (w/v) for tolerability reasons; the bioavailability was reduced to 15.3 and 20.5% in these cases, respectively.",Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1589410/),%,15.3,168560,DB00104,Octreotide
,1589410,bioavailability,"The enhancement of nasal absorption was dependent on the STDHF concentrations as shown by decreasing the amounts to 1.2 and 0.8% (w/v) for tolerability reasons; the bioavailability was reduced to 15.3 and 20.5% in these cases, respectively.",Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1589410/),%,20.5,168561,DB00104,Octreotide
,1517834,T 1/2,The 123I-octreotide was rapidly cleared from the blood with a T 1/2 of 10 min by the hepatobiliary system.,Dosimetry and biodistribution of an iodine-123-labeled somatostatin analog in patients with neuroendocrine tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517834/),min,10,169661,DB00104,Octreotide
,9701530,extraction fraction,The extraction fraction of octreotide in the liver was 0.05 (-0.01 - 0.14) (median (interquartile range)) and in the kidneys 0.16 (-0.06 - 0.35).,The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701530/),,0.05,181005,DB00104,Octreotide
,9701530,extraction fraction,The extraction fraction of octreotide in the liver was 0.05 (-0.01 - 0.14) (median (interquartile range)) and in the kidneys 0.16 (-0.06 - 0.35).,The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701530/),,0.16,181006,DB00104,Octreotide
,9701530,extraction fraction ratio (E,The extraction fraction ratio (E(liver)/E(kidney)) was 0.69 (-0.20 - 1.06).,The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701530/),,0.69,181007,DB00104,Octreotide
,9701530,Hepatic clearance,Hepatic clearance was 47 mL/min (3-88) (n = 11).,The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701530/),[ml] / [min],47,181008,DB00104,Octreotide
,17994644,limit of detection,The limit of detection was 0.0200 ng/mL.,"Determination of long-acting release octreotide, an octapeptide analogue of somatostation, in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17994644/),[ng] / [ml],0.0200,187345,DB00104,Octreotide
,21700513,total chromatographic run time,"Octreotide and its labeled internal standard, [(13)C(6)Phe(3)] octreotide, were extracted from human plasma using a simple Oasis® WCX μElution SPE method and analyzed with a total chromatographic run time of 7.5 min.",Determination of octreotide and assessment of matrix effects in human plasma using ultra high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700513/),min,7.5,190582,DB00104,Octreotide
,21700513,Recovery,Recovery was ∼73%.,Determination of octreotide and assessment of matrix effects in human plasma using ultra high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700513/),%,∼73,190583,DB00104,Octreotide
<,29188801,bioavailability,"The pharmacokinetic studies in rats showed that intragastric administration of OCT had extremely low bioavailability (<0.5%), but it could specifically distribute to the gastric mucosa due to the high expression of somatostatin receptor 2 (SSTR2) in the rat stomach.",Pharmacokinetic and pharmacodynamic evidence for developing an oral formulation of octreotide against gastric mucosal injury. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29188801/),%,0.5,196253,DB00104,Octreotide
,1349039,effective dose equivalent,The calculated effective dose equivalent is 0.08 mSv/MBq.,"Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1349039/),[msv] / [Mbq],0.08,196425,DB00104,Octreotide
,21329733,total uptake,"Oral delivery of octreotide acetate in 0.5% Intravail® significantly enhanced total uptake (1254.08ng/ml/min vs. 311.63ng/ml/min, respectively), serum half-life (52.1min vs. 1.3min, respectively), and relative bioavailability (4.0 vs.","Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329733/),[ng] / [min·ml],1254.08,211932,DB00104,Octreotide
,21329733,total uptake,"Oral delivery of octreotide acetate in 0.5% Intravail® significantly enhanced total uptake (1254.08ng/ml/min vs. 311.63ng/ml/min, respectively), serum half-life (52.1min vs. 1.3min, respectively), and relative bioavailability (4.0 vs.","Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329733/),[ng] / [min·ml],311.63,211933,DB00104,Octreotide
,21329733,serum half-life,"Oral delivery of octreotide acetate in 0.5% Intravail® significantly enhanced total uptake (1254.08ng/ml/min vs. 311.63ng/ml/min, respectively), serum half-life (52.1min vs. 1.3min, respectively), and relative bioavailability (4.0 vs.","Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329733/),min,52.1,211934,DB00104,Octreotide
,21329733,serum half-life,"Oral delivery of octreotide acetate in 0.5% Intravail® significantly enhanced total uptake (1254.08ng/ml/min vs. 311.63ng/ml/min, respectively), serum half-life (52.1min vs. 1.3min, respectively), and relative bioavailability (4.0 vs.","Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329733/),min,1.3,211935,DB00104,Octreotide
,21329733,relative bioavailability,"Oral delivery of octreotide acetate in 0.5% Intravail® significantly enhanced total uptake (1254.08ng/ml/min vs. 311.63ng/ml/min, respectively), serum half-life (52.1min vs. 1.3min, respectively), and relative bioavailability (4.0 vs.","Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21329733/),,4.0,211936,DB00104,Octreotide
,2876508,initial half-lives,After intravenous administration of SMS 201-995 initial half-lives ranging from 9 +/- 2 min to 14 +/- 4 min and second half-lives of from 72 +/- 22 min to 98 +/- 37 min were calculated for the different doses.,Pharmacokinetics of SMS 201-995 in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876508/),min,9,226288,DB00104,Octreotide
,2876508,initial half-lives,After intravenous administration of SMS 201-995 initial half-lives ranging from 9 +/- 2 min to 14 +/- 4 min and second half-lives of from 72 +/- 22 min to 98 +/- 37 min were calculated for the different doses.,Pharmacokinetics of SMS 201-995 in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876508/),min,14,226289,DB00104,Octreotide
,2876508,second half-lives,After intravenous administration of SMS 201-995 initial half-lives ranging from 9 +/- 2 min to 14 +/- 4 min and second half-lives of from 72 +/- 22 min to 98 +/- 37 min were calculated for the different doses.,Pharmacokinetics of SMS 201-995 in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876508/),min,72,226290,DB00104,Octreotide
,2876508,second half-lives,After intravenous administration of SMS 201-995 initial half-lives ranging from 9 +/- 2 min to 14 +/- 4 min and second half-lives of from 72 +/- 22 min to 98 +/- 37 min were calculated for the different doses.,Pharmacokinetics of SMS 201-995 in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876508/),min,98,226291,DB00104,Octreotide
,2876508,half-life,SMS 201-995 was rapidly absorbed after subcutaneous injection with a half-life ranging from 5.3 +/- 2.2 min to 11.7 +/- 7.6 min.,Pharmacokinetics of SMS 201-995 in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876508/),min,5.3,226292,DB00104,Octreotide
,2876508,half-life,SMS 201-995 was rapidly absorbed after subcutaneous injection with a half-life ranging from 5.3 +/- 2.2 min to 11.7 +/- 7.6 min.,Pharmacokinetics of SMS 201-995 in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876508/),min,11.7,226293,DB00104,Octreotide
,2876508,disposition half-life,The disposition half-life was from 88 +/- 20 min to 102 +/- 16 min for the different doses.,Pharmacokinetics of SMS 201-995 in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876508/),min,88,226294,DB00104,Octreotide
,2876508,disposition half-life,The disposition half-life was from 88 +/- 20 min to 102 +/- 16 min for the different doses.,Pharmacokinetics of SMS 201-995 in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876508/),min,102,226295,DB00104,Octreotide
,8295005,accumulation,"After 1 hr, the accumulation of 67Ga[DFO]-octreotide was 0.38 +/- 0.08 %ID/g and the tumor-to-nontumor ratios for blood, muscle, liver and intestine were 2.5, 7.4, 1.9 and 1.6, respectively.",Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295005/),[%id] / [g],0.38,226440,DB00104,Octreotide
,8295005,tumor-to-nontumor ratios,"After 1 hr, the accumulation of 67Ga[DFO]-octreotide was 0.38 +/- 0.08 %ID/g and the tumor-to-nontumor ratios for blood, muscle, liver and intestine were 2.5, 7.4, 1.9 and 1.6, respectively.",Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295005/),,2.5,226441,DB00104,Octreotide
,8295005,tumor-to-nontumor ratios,"After 1 hr, the accumulation of 67Ga[DFO]-octreotide was 0.38 +/- 0.08 %ID/g and the tumor-to-nontumor ratios for blood, muscle, liver and intestine were 2.5, 7.4, 1.9 and 1.6, respectively.",Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295005/),,7.4,226442,DB00104,Octreotide
,8295005,tumor-to-nontumor ratios,"After 1 hr, the accumulation of 67Ga[DFO]-octreotide was 0.38 +/- 0.08 %ID/g and the tumor-to-nontumor ratios for blood, muscle, liver and intestine were 2.5, 7.4, 1.9 and 1.6, respectively.",Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295005/),,1.9,226443,DB00104,Octreotide
,8295005,tumor-to-nontumor ratios,"After 1 hr, the accumulation of 67Ga[DFO]-octreotide was 0.38 +/- 0.08 %ID/g and the tumor-to-nontumor ratios for blood, muscle, liver and intestine were 2.5, 7.4, 1.9 and 1.6, respectively.",Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295005/),,1.6,226444,DB00104,Octreotide
,8295005,residence half-life,PET studies with 68Ga[DFO]-octreotide recorded a very rapid accumulation at the tumor and a subsequent residence half-life of about 6 hr.,Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295005/),h,6,226445,DB00104,Octreotide
,21948321,steady-state octreotide serum drug levels,"Using pharmacokinetic computer simulations, it was estimated that the steady-state octreotide serum drug levels would be predicted to fall in the range of 40-130 pg/10 μL and 20-100 pg/10 μL following repeat dosing of the Oakwood formulations and Sandostatin LAR(®) every 28 days and every 42 days at a dose of 3 mg/rat, respectively.",Sustained-release delivery of octreotide from biodegradable polymeric microspheres. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21948321/),[pg] / [10·μl],40-130,227811,DB00104,Octreotide
,21948321,steady-state octreotide serum drug levels,"Using pharmacokinetic computer simulations, it was estimated that the steady-state octreotide serum drug levels would be predicted to fall in the range of 40-130 pg/10 μL and 20-100 pg/10 μL following repeat dosing of the Oakwood formulations and Sandostatin LAR(®) every 28 days and every 42 days at a dose of 3 mg/rat, respectively.",Sustained-release delivery of octreotide from biodegradable polymeric microspheres. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21948321/),μl,20-100,227812,DB00104,Octreotide
,2364560,t1/2abs,Octreotide was rapidly absorbed with a mean (+/- SEM) t1/2abs of 5.4 min (+/- 0.8) peaking at a mean plasma concentration of 3.4 nmol/l (+/- 0.2) in 27.4 min (+/- 3.7).,Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2364560/),min,5.4,228261,DB00104,Octreotide
,2364560,plasma concentration,Octreotide was rapidly absorbed with a mean (+/- SEM) t1/2abs of 5.4 min (+/- 0.8) peaking at a mean plasma concentration of 3.4 nmol/l (+/- 0.2) in 27.4 min (+/- 3.7).,Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2364560/),,3,228262,DB00104,Octreotide
,2364560,half-life,The monoexponential elimination phase had a mean half-life of 110 min (+/- 9.6).,Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2364560/),min,110,228263,DB00104,Octreotide
,2364560,apparent volume of distribution,The apparent volume of distribution was 29.4 1 (+/- 1.9) and total clearance was 172 ml/min (+/- 10.4).,Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2364560/),1,29.4,228264,DB00104,Octreotide
,2364560,total clearance,The apparent volume of distribution was 29.4 1 (+/- 1.9) and total clearance was 172 ml/min (+/- 10.4).,Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2364560/),[ml] / [min],172,228265,DB00104,Octreotide
,2407389,peaks,"Insulin peaks at 30 minutes were blunted from 65.8 +/- 11.0 mu U/mL without treatment to 26.7 +/- 8.6 mu U/mL and 7.7 +/- 2.0 mu U/mL after the 50- and 100-micrograms doses, respectively.",Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (sandostatin). Effect on pancreatic and thyroid hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407389/),[mu·u] / [ml],65.8,229120,DB00104,Octreotide
,2407389,peaks,"Insulin peaks at 30 minutes were blunted from 65.8 +/- 11.0 mu U/mL without treatment to 26.7 +/- 8.6 mu U/mL and 7.7 +/- 2.0 mu U/mL after the 50- and 100-micrograms doses, respectively.",Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (sandostatin). Effect on pancreatic and thyroid hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407389/),[mu·u] / [ml],26.7,229121,DB00104,Octreotide
,2407389,peaks,"Insulin peaks at 30 minutes were blunted from 65.8 +/- 11.0 mu U/mL without treatment to 26.7 +/- 8.6 mu U/mL and 7.7 +/- 2.0 mu U/mL after the 50- and 100-micrograms doses, respectively.",Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (sandostatin). Effect on pancreatic and thyroid hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407389/),[mu·u] / [ml],7.7,229122,DB00104,Octreotide
longer,2407389,half-life,The plasma peak of SMS 210-995 occurred 30 minutes postinjection and half-life was longer than 2 hours.,Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (sandostatin). Effect on pancreatic and thyroid hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407389/),h,2,229123,DB00104,Octreotide
,15783069,distribution,"The distribution and elimination half-life for 125I-REAL-TOC were 1.4 h and 6.6 h, respectively, which were significantly longer than those of 125I-TOC.","Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15783069/),h,1.4,236652,DB00104,Octreotide
,15783069,elimination half-life,"The distribution and elimination half-life for 125I-REAL-TOC were 1.4 h and 6.6 h, respectively, which were significantly longer than those of 125I-TOC.","Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15783069/),h,6.6,236653,DB00104,Octreotide
,29736841,elimination rate constant (k10),"AA co-infusion had a significant effect ('fixed effect') on 177Lu-Dotatate pharmacokinetics, with a mean value of 1.5-fold (95% confidence interval 1.03-1.97) increase in the elimination rate constant (k10) from 0.204 to 0.306 h-1, but this AA co-infusion effect was associated with a large inter-individual variability (IIV) of 104%.",Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29736841/),1/[h],0.204,239700,DB00104,Octreotide
,29736841,elimination rate constant (k10),"AA co-infusion had a significant effect ('fixed effect') on 177Lu-Dotatate pharmacokinetics, with a mean value of 1.5-fold (95% confidence interval 1.03-1.97) increase in the elimination rate constant (k10) from 0.204 to 0.306 h-1, but this AA co-infusion effect was associated with a large inter-individual variability (IIV) of 104%.",Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29736841/),1/[h],0.306,239701,DB00104,Octreotide
lower,29736841,k10,"The individual k10 values increased during concomitant AA infusion by a factor ranging from 1.01 to 21.3 for 27 patients, whereas the opposite effect was observed in 15 patients (range 0.36-0.99) of whom seven had a k10 value lower than 0.85.",Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29736841/),,0.85,239702,DB00104,Octreotide
,12236784,tumor uptake,"While tumor uptake of [(125)I]TOC (6.7 +/- 2.6%ID/g), [(125)I]Malt-TOC (5.3 +/- 1.9%ID/g), and [(125)I]Mtr-TOC (4.9 +/- 2.2%ID/g) at 30 min postinjection was comparable, accumulation of [(125)I]Gluc-TOC was significantly increased (10.1 +/- 2.8%ID/g at 30 min pi).",Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236784/),[%id] / [g],6.7,239902,DB00104,Octreotide
,12236784,tumor uptake,"While tumor uptake of [(125)I]TOC (6.7 +/- 2.6%ID/g), [(125)I]Malt-TOC (5.3 +/- 1.9%ID/g), and [(125)I]Mtr-TOC (4.9 +/- 2.2%ID/g) at 30 min postinjection was comparable, accumulation of [(125)I]Gluc-TOC was significantly increased (10.1 +/- 2.8%ID/g at 30 min pi).",Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236784/),[%id] / [g],5.3,239903,DB00104,Octreotide
,12236784,tumor uptake,"While tumor uptake of [(125)I]TOC (6.7 +/- 2.6%ID/g), [(125)I]Malt-TOC (5.3 +/- 1.9%ID/g), and [(125)I]Mtr-TOC (4.9 +/- 2.2%ID/g) at 30 min postinjection was comparable, accumulation of [(125)I]Gluc-TOC was significantly increased (10.1 +/- 2.8%ID/g at 30 min pi).",Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236784/),[%id] / [g],4.9,239904,DB00104,Octreotide
,25771362,half life,Lutetium-177 ((177)Lu) is a rare earth metal in the lanthanides series which decays by beta emission with a half life of 6.647 days to three excited states and the ground state of (177)Hf.,Consequences of meta-stable (177m)Lu admixture in (177)Lu for patient dosimetry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25771362/),d,6.647,240832,DB00104,Octreotide
,25771362,half-life,"As its half-life of 160.4 days is so much longer than that of (177)Lu, concerns are raised on its possible enhancement in radiation dose to the patient treated with (177)Lu-DOTA-octreotate.",Consequences of meta-stable (177m)Lu admixture in (177)Lu for patient dosimetry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25771362/),d,160.4,240833,DB00104,Octreotide
,8050122,IGF-I,Basal mean IGF-I value for all 11 patients was 716 +/- 96 micrograms/l.,Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8050122/),[μg] / [l],716,257580,DB00104,Octreotide
,7596072,half life,"The plasma clearance curve consisted of fast and slow exponential components with mean half life of 9.2 minutes and 2.2 hours, respectively.","[Clinical evaluation of safety, pharmacokinetics and dosimetry of the somatostatin analog 111In-DTPA-D-Phe-octreotide--report of the phase 1 study]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596072/),min,9.2,262378,DB00104,Octreotide
,7596072,half life,"The plasma clearance curve consisted of fast and slow exponential components with mean half life of 9.2 minutes and 2.2 hours, respectively.","[Clinical evaluation of safety, pharmacokinetics and dosimetry of the somatostatin analog 111In-DTPA-D-Phe-octreotide--report of the phase 1 study]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596072/),h,2.2,262379,DB00104,Octreotide
,7596072,effective dose equivalent,The effective dose equivalent was calculated as 3.26 +/- 0.43 mSv/37 MBq (mean +/- s.d.).,"[Clinical evaluation of safety, pharmacokinetics and dosimetry of the somatostatin analog 111In-DTPA-D-Phe-octreotide--report of the phase 1 study]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596072/),[msv] / [37·Mbq],3.26,262380,DB00104,Octreotide
,7911441,elimination half life,The elimination half life is about 1.5 hours and about 32% of a subcutaneous dose is excreted in the urine as unchanged octreotide.,Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7911441/),h,1.5,263089,DB00104,Octreotide
,19194215,Emax,"In particular, the pure high-energy beta-emitter 90Y (Emax=2.27 MeV) has a physical half-life compatible with the pharmacokinetics of peptides.",Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194215/),Mev,2.27,266684,DB00104,Octreotide
,19194215,skin equivalent dose distribution,The 95th percentile of the chemist's skin equivalent dose distribution was 1.759 mSv/GBq by using 0.10-mm anti-X gloves and 0.265 mSv/GBq by using 0.20-mm anti-X gloves.,Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194215/),[msv] / [gbq],1.759,266685,DB00104,Octreotide
,19194215,skin equivalent dose distribution,The 95th percentile of the chemist's skin equivalent dose distribution was 1.759 mSv/GBq by using 0.10-mm anti-X gloves and 0.265 mSv/GBq by using 0.20-mm anti-X gloves.,Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194215/),[msv] / [gbq],0.265,266686,DB00104,Octreotide
,19194215,skin equivalent dose distribution,The 95th percentile of the physician's skin equivalent dose distribution was 1.198 mSv/GBq by using 0.10-mm anti-X gloves.,Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194215/),[msv] / [gbq],1.198,266687,DB00104,Octreotide
,11994362,MCRs,"During primed constant infusions of GH at rates of 1.5 and 3.0 microg/kg x h, the corresponding MCRs of GH were 148.8 +/- 5.4 and 89.8 +/- 2.4 ml/min x m(-2), respectively, and the MCRs were inversely related to the achieved steady state GH levels (P < 0.0001).","Body composition and circulating levels of insulin, insulin-like growth factor-binding protein-1 and growth hormone (GH)-binding protein affect the pharmacokinetics of GH in adults independently of age. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994362/),[min·ml] / [(m)^2],148.8,272323,DB00104,Octreotide
,11994362,MCRs,"During primed constant infusions of GH at rates of 1.5 and 3.0 microg/kg x h, the corresponding MCRs of GH were 148.8 +/- 5.4 and 89.8 +/- 2.4 ml/min x m(-2), respectively, and the MCRs were inversely related to the achieved steady state GH levels (P < 0.0001).","Body composition and circulating levels of insulin, insulin-like growth factor-binding protein-1 and growth hormone (GH)-binding protein affect the pharmacokinetics of GH in adults independently of age. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994362/),[min·ml] / [(m)^2],89.8,272324,DB00104,Octreotide
